Alexion Pharmaceuticals, Inc.
DOSAGE AND ADMINISTRATION OF ANTI-C5 ANTIBODIES FOR TREATMENT OF ATYPICAL HEMOLYTIC UREMIC SYNDROME (AHUS)
Last updated:
Abstract:
Provided are methods for clinical treatment of Atypical Hemolytic Uremic Syndrome (aHUS) using an anti-C5 antibody, or antigen binding fragment thereof.
Status:
Application
Type:
Utility
Filling date:
24 Jan 2020
Issue date:
28 Jul 2022